Evidence map›Paper›PMID 31557998›Full record

ReviewAntibodies (Basel, Switzerland)2016

Antiphospholipid Syndrome and Kidney Involvement: New Insights.

José A Martínez-Flores, Manuel Serrano, Jose M Morales, Antonio Serrano

Abstract readReview
In one paragraph

Review in Antibodies (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

José A Martínez-FloresDepartment of Immunology, Instituto de Investigación Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. martinezfloresja@gmail.com.
Manuel SerranoDepartment of Immunology, Instituto de Investigación Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. mserranobl@gmail.com.
Jose M MoralesDepartment of Immunology, Instituto de Investigación Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. jmorales@h12o.es.
Antonio SerranoDepartment of Immunology, Instituto de Investigación Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. aserrano@h12o.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiphospholipid syndrome is an autoimmune disorder characterized by vascular thromboses and pregnancy morbidity associated with antiphospholipid antibodies: lupus anticoagulant, IgG or IgM anticardiolipin or anti-beta 2-glycoprotein I. The kidney is one of the major target organs in antiphospholipid syndrome (APS). However, beyond the known involvement of the kidney in primary and associated APS, we may be observing a new form of APS within the context of renal failure. This review describes the classical kidney manifestations of APS and provides new considerations to be taken into account.

Indexed as

antiphospholipid antibodiesaPLautoimmunityB2GPIearly graft lossend stage kidney diseaseIgAthrombosis antiphospholipid syndrome

Identifiers

PMID31557998
PMCPMC6698833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.